Question explored with the scientific record
Does ivermectin cure some cancers
The short version: no human trial has shown ivermectin cures any cancer. The cancer evidence is lab-dish and computer-model work, not outcomes in people.
The strongest human data in this retrieval is not about curing cancer at all. In Loja, Ecuador, about 19 in 100 cancer patients were self-medicating with ivermectin despite no scientific endorsement for it in cancer therapy, and some reported side effects like diarrhea and skin blisters [1]. Two case reports show ivermectin used to treat parasitic infections in cancer patients, not the cancer itself: one man with bladder cancer died within a week of treatment [2], and another with lung cancer cleared a Strongyloides infection and survived [4]. Neither shows the drug touched the tumor.
The mechanistic claims are preclinical. A 2019 study found ivermectin triggered autophagy (a cell-recycling process) and death in glioma cells in the lab, and combining it with chloroquine boosted the effect in mice [5]. A 2025 colorectal paper used single-cell sequencing to flag ivermectin as a "potential adjunct" based on a predictive model, not a treated patient [3]. That is a hypothesis, not a cure.
| Evidence type | What it shows | Human cancer outcome? |
|---|---|---|
| Ecuador survey [1] | 19% self-medicate; side effects reported | No |
| Bladder cancer case [2] | Died within 1 week of ivermectin | No |
| Lung cancer case [4] | Parasite cleared, patient survived | No |
| Glioma lab study [5] | Cell death in vitro, mice | No |
| Colorectal model [3] | "Potential adjunct" prediction | No |
This search surfaced no randomized trial of ivermectin as a cancer treatment in humans. That absence is a fact about this retrieval, not proof none exists. What would settle it: a controlled trial measuring tumor shrinkage or survival, not lab markers.
My call: the evidence does not support ivermectin as a cancer cure, and anyone selling it that way is selling hope without human outcome data. Confidence: moderate that no human cure evidence exists in this retrieval; low on the broader literature.
Sources used 5
-
Outcome of Ivermectin in Cancer Treatment: An Experience in Loja-Ecuador
This study investigates the use of ivermectin as an alternative treatment for cancer in rural areas of Loja, Ecuador, revealing that a significant percentage of cancer patients self-medicate with this antiparasitic drug despite a lack of scientific endorsement for its efficacy i…
DOI: 10.3390/nursrep13010030 -
Strongyloides stercoralis larvae in the urine of a patient with transitional cell carcinoma of the bladder: a case report
A Nigerian case report describing disseminated Strongyloides stercoralis infection with larvae detected in the urine of a 60-year-old man with transitional cell carcinoma of the bladder, treated with ivermectin, who died within a week, highlighting the need to suspect strongyloi…
DOI: 10.1007/s12639-018-1051-6 -
Single-cell RNA sequencing reveals neutrophil differentiation-related genes for immunotherapy response prediction in colorectal cancer
Single-cell RNA sequencing of colorectal cancer reveals neutrophil differentiation–related genes that predict immunotherapy response and identifies Ivermectin as a potential adjunct therapeutic strategy.
DOI: 10.1186/s12885-025-15355-7 -
A Case Report of Disseminated Strongyloidiasis Following Chemoradiotherapy for Lung Cancer in a Patient Living in a Non-endemic Area in Japan
This case report documents HTLV-1-associated disseminated Strongyloides stercoralis infection developing after chemoradiotherapy for lung cancer in a non-endemic area of Japan, successfully treated with daily ivermectin followed by six months of intermittent dosing, highlighting…
DOI: 10.2169/internalmedicine.5829-25 -
Ivermectin induces autophagy-mediated cell death through the AKT/mTOR signaling pathway in glioma cells
Ivermectin triggers autophagy through AKT/mTOR inhibition in glioma cells; autophagy protects against IVM-induced apoptosis in vitro, and combining with chloroquine enhances anti-glioma effects in vivo.
DOI: 10.1042/bsr20192489